United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - aspirin - gastro-resistant tablet - 300mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - aspirin - gastro-resistant tablet - 300mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - aspirin - gastro-resistant tablet - 300mg

United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e) - aspirin 325 mg - pain reliever/fever reducer temporarily relieves • headache • toothache • minor pain of arthritis • muscle pain • pain and fever of colds • menstrual pain

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - aspirin, quantity: 100 mg; clopidogrel hydrogen sulfate, quantity: 97.875 mg (equivalent: clopidogrel, qty 75 mg) - tablet, film coated - excipient ingredients: hyprolose; mannitol; carnauba wax; colloidal anhydrous silica; maize starch; microcrystalline cellulose; hydrogenated castor oil; stearic acid; macrogol 6000; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide red - apx-clopidogrel is a fixed-dose combination product intended as continuation of therapy in patients with acute coronary syndrome already initiated with separate clopidogrel and aspirin products: unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). apx-clopidogrel is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent). st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, apx-clopidogrel has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - aspirin, quantity: 100 mg; clopidogrel hydrogen sulfate, quantity: 97.87 mg (equivalent: clopidogrel, qty 75 mg) - tablet - excipient ingredients: lactose; hydrogenated castor oil; microcrystalline cellulose; crospovidone; glycerol dibehenate; colour - clopidogrel/aspirin is a fixed-dose combination product.,clopidogrel/aspirin is intended as continuation of therapy in patients with acute coronary syndrome already initiated with separate clopidogrel and aspirin products: unstable angina or non-st elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). clopidogrel/aspirin is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent); st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, clopidogrel/aspirin has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - aspirin - oral tablet - 300mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

numark ltd - aspirin - oral tablet - 300mg

United Kingdom - English - myHealthbox

aptil pharma limited - aspirin - gastro-resistant tablets - 75mg - antithrombotic agents: platelet aggregation inhibitors excl. heparin - − secondary prevention of myocardial infarction. − prevention of cardiovascular morbidity in patients suffering from stable angina pectoris. − history of unstable angina pectoris, except during the acute phase. − prevention of graft occlusion after coronary artery bypass grafting (cabg). − coronary angioplasty, except during the acute phase. − secondary prevention of transient ischaemic attacks (tia) and ischaemic cerebrovascular accidents (cva), provided intracerebral haemorrhages have been ruled out.

United States - English - NLM (National Library of Medicine)

prime marketing, llc - aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e) - aspirin 81 mg - pain reliever - for the temporary relief of minor aches and pains - ask your doctor about other uses for aspirin